Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(13 sites)

France

CHRU Bordeaux, Bordeaux

CHRU Lille, Lille

HCL - Lyon Sud, Lyon

HCL, Lyon

Hôpital pour enfants - La Timone, Marseille

CHU Montpellier - Hopital Arnaud de Villeneuve, Montpellier

CHU Nancy, Nancy

CHU Nantes - Hopital Mère-enfants, Nantes

Robert Debre hospital, Paris

Saint Louis hospital, Paris

CHU Rouen, Rouen

CHRU Strasbourg, Strasbourg